ARGEN-X
To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.
ARGEN-X
Industry:
Biotechnology Clinical Trials Therapeutics
Founded:
2008-01-01
Address:
Rotterdam, Zuid-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.argenx.com
Total Employee:
501+
Status:
Active
Contact:
+320477772944
Email Addresses:
[email protected]
Total Funding:
1.95 B USD
Technology used in webpage:
IPhone / Mobile Compatible SPF Domain Not Resolving Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS ASP.NET IIS Sectigo SSL Sectigo Domain SSL
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Immunovia
Immunovia is the center for translational cancer research in Lund, Sweden.
X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
Current Employees Featured
Founder
Stock Details
Investors List
Burrage Capital
Burrage Capital investment in Post-IPO Equity - arGEN-X
MPM Capital
MPM Capital investment in Post-IPO Equity - arGEN-X
Dafna Capital Management
Dafna Capital Management investment in Post-IPO Equity - arGEN-X
Aquila Capital
Aquila Capital investment in Post-IPO Equity - arGEN-X
Erasmus MC Biomedical Fund
Erasmus MC Biomedical Fund investment in Series B - arGEN-X
PMV
PMV investment in Series B - arGEN-X
Omnes Capital
Omnes Capital investment in Series B - arGEN-X
Seventure Partners
Seventure Partners investment in Series B - arGEN-X
OrbiMed
OrbiMed investment in Series B - arGEN-X
Forbion Capital Partners
Forbion Capital Partners investment in Series B - arGEN-X
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-02-06 | Halozyme Therapeutics | arGEN-X investment in Post-IPO Equity - Halozyme Therapeutics | 30 M USD |
Official Site Inspections
http://www.argenx.com Semrush global rank: 467.41 K Semrush visits lastest month: 110.13 K
- Host name: 151.101.3.10
- IP address: 151.101.3.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "arGEN-X"
argenx - Crunchbase Company Profile & Funding
Argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.See details»
argenx | Innovation - The Science of Collaboration
The Immunology Innovation Program (IIP) is a core business strategy of argenx connecting the specialized insight into disease and target biology of our external scientific and academic …See details»
argenx | About - One Team, One Culture, …
At argenx, we build our culture from the collective power of the team and the knowledge that together, we are better. We are all co-owners of this company; we recognize that each individual …See details»
argenx - Leadership Team | The Org
The Leadership Team at argenx is responsible for guiding the strategic direction and operational excellence of the company. Composed of executives across various domains including …See details»
argenx | Homepage - Reaching Patients Through Immunology …
At argenx, we’ve created an antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side to accelerate the discovery of novel targets, disease …See details»
Company Profile - argenx Annual Report 2024
Apr 25, 2008 argenx Austria Services GmbH, incorporated under the laws of Austria, having its registered office and address at Graben 19, 4th & 5th floor Vienna A-1010 Austria. The …See details»
argenx Reports Half Year 2025 Financial Results and Provides …
Jul 31, 2025 argenx has established its strategic priorities to advance Vision 2030, aiming to treat 50,000 patients globally with its medicines, secure 10 labeled indications across all …See details»
argenx | Governance
Argenx has a one-tier board consisting of executive and non-executive directors, and an executive management team responsible for the day-to-day operations of the company.See details»
argenx | Patients - Our Commitment to Patients
Argenx is proud to sponsor MG United Canada. MG United Canada was created to support Canadians living with MG and those who care for them, by providing helpful resources that …See details»
Organization and Operations - argenx Annual Report 2022
Risk Factors Related to argenx’s Organization and Operations Our Future Growth and Ability to Compete Depends on Retaining our Key Personnel and Recruiting Additional Qualified …See details»
The argenx way
The argenx Way is who we are and how we work together– it guides everything we do and how we continue to transform immunology.See details»
argenx | Ethics and Responsibility | Argenx
At argenx, we build our culture from the collective power of the team and the knowledge that together, we are better. We align our personal growth with the shared goals of the organization …See details»
Ethics and Responsibility - Argenx
Written Standards argenx has established policies and procedures, including our Code of Business Conduct and Ethics, which articulate our fundamental principles and values and …See details»
Governance - argenx Annual Report 2024
Governance Introduction to Corporate Culture at argenx (ESRS 2 SBM-3, G1-1) We have put in place governance structures and mechanisms to promote accountability, adaptability, and …See details»
argenx | Our Story
The science of co-creation drives our quest to engineer life-changing immunology solutions, the resilient spirit of patients fuels our urgency to deliver them.See details»
Annual Report 2021 - argenx.com
Argenx SE (herein argenx or the Company and, together with its subsidiaries, the Group, we or us) is a European public company (Societas Europaea) incorporated under the laws of the …See details»
argenx | Board of Directors
Tim Van Hauwermeiren co-founded argenx and has served as Chief Executive Officer since April 2008. He has been a member of the Board of Directors since July 2014. Tim has more than 20 …See details»
argenx Careers
Explore career opportunities at argenx, a company dedicated to developing innovative immunology solutions and fostering a culture of collaboration and possibility.See details»
Code of Business Conduct and Ethics - Argenx
Who we are – Our DNA At argenx, we build our culture from the collective power of the team and the knowledge that together, we are better. We are all co-owners of this company; we …See details»
Social - argenx Annual Report 2024
Argenx was founded on a model of co-creation and this core element of our entrepreneurial spirit remains widespread across the organization today, underpinning every step of our drug …See details»